Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1819 in Prurigo Nodularis
NCT06554509Phase 3Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2024
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prurigo nodularis (PN) comparing SHR-1819 Injection Group with SHR-1819 Injection Placebo Group (2 arms). Primary endpoint: Proportion of subjects with a ≥ 4-point reduction from baseline in the weekly mean of the Most Intense Pruritus Numeric Rating Scale at 24 weeks. Started Sep 2024; status: recruiting.
02
Drugs
SHR-1819
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT06554509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554509.